EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A randomized study of methotrexate bleomycin hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck



A randomized study of methotrexate bleomycin hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck



European Journal of Cancer & Clinical Oncology 23(1): 47-54



The value of a combination of methotrexate, bleomycin and hydroxyurea with vs. without cisplatin was randomly examined in 62 evaluable patients with previously untreated (44 patients) and recurrent (18 patients) squamous cell carcinoma of the head and neck. Methotrexate (30 mg/m2) and bleomycin (15 mg) were given intravenously weekly, hydroxyurea (1000 mg/m2) per os 3 times per week for 4 weeks. Cisplatin (60 mg/m2) was added on Day 1 every month. A higher overall response rate was observed with the cisplatin-containing regimen (66%, included 17% complete) as compared with 27% (3% complete) with the 3-drug combination (P value 0.0025). The cisplatin-containing regimen was more active in both previously untreated patient group and in the group of recurrent patients. Toxicity was more pronounced in the cisplatin regimen and necessitated frequently reduced drug dosages. No survival difference was observed between the treatment groups. Median survival in previously untreated patients was 16.2 months and 7.2 months in patients who failed conventional local treatment. It is concluded that a cisplatin-containing regimen is more effective in advanced head and neck carcinoma than the same combination without cisplatin.

(PDF emailed within 0-6 h: $19.90)

Accession: 004615545

Download citation: RISBibTeXText

PMID: 2439344

DOI: 10.1016/0277-5379(87)90418-4



Related references

Methotrexate bleomycin hydroxyurea vs methotrexate bleomycin hydroxyurea and cisplatin in stage iii iv squamous cell carcinoma of the head and neck a randomized study. 1984

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology 5(6): 521-526, 1994

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology 5(6): 521-526, 1994

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. Oncologist 21(12): 1416-1e17, 2016

Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK). Progress in Clinical and Biological Research 201: 169-175, 1985

A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52(2): 206-210, 1983

Randomized comparison of cis-diamminedichloroplatinum versus cis-diamminedichloroplatinum, methotrexate, and bleomycin in recurrent squamous cell carcinoma of the head and neck. Cancer ChemoTherapy and Pharmacology 3(1): 57-59, 1979

Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology 18(4): 293-296, 1995

Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. RadioTherapy and Oncology 100(1): 62-69, 2011

Cisplatin and bleomycin in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck. A randomized facultative Phase III controlled study. Sonderbande Zur Strahlentherapie und Onkologie 81: 141-150, 1987

A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck. Cancer 52(3): 399-403, 1983

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. Journal of Clinical Oncology 13(7): 1649-1655, 1995

Randomized trial of cisplatin methotrexate bleomycin and vincristine vs adriamycin bleomycin and vincristine in advanced squamous cell carcinoma of the head and neck. 1984

Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer ChemoTherapy and Pharmacology 66(4): 729-736, 2010

Randomized trial of cis platin methotrexate bleomycin vincristine vs cis platin and 5 fluorouracil vs cisplatin alone in patients with advanced squamous cell carcinoma of the head and neck. 1986